1 The FLOW trial achieved its primary endpoint with Ozempic 1 mg, demonstrating a statistically significant and superior 24% relative risk reduction of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease (4.9% absolute risk reduction at 3 years) compared to placebo, when added to standard of care
Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, et al
Lipogenic genes are nonoscillatory in ovariectomized and liver ER knockout mice where greater liver lipid accumulation is observed in the livers (10)
Detoxification: It aids with flushing toxins out of the body via the liver and can thus minimise problems such as skin issues caused by impurity, acne, as well as dullness
P., & Takeuchi, K
Gutman managed a wide range of medical emergencies with limited resources